These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1098 related items for PubMed ID: 11509937

  • 1. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ, Antin JH, Wolff SN, Bierer BE, Small T, Miller KB, Linker C, Kaizer H, Lazarus HM, Petersen FB, Cowan MJ, Ho WG, Wingard JR, Schiller GJ, Territo MC, Jiao J, Petrarca MA, Tonetta SA.
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [Abstract] [Full Text] [Related]

  • 2. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ, Ho WG, Bartoni K, Champlin RE.
    Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
    [Abstract] [Full Text] [Related]

  • 3. Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts.
    Engelhard D, Morag A, Or R, Naparstek E, Cividalli G, Ruchlemer R, Aker M, Maayan S, Slavin S.
    Isr J Med Sci; 1988 Mar; 24(3):145-50. PubMed ID: 3286577
    [Abstract] [Full Text] [Related]

  • 4. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
    Zikos P, Van Lint MT, Lamparelli T, Gualandi F, Occhini D, Mordini N, Berisso G, Bregante S, Bacigalupo A.
    Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
    [Abstract] [Full Text] [Related]

  • 5. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, Harrousseau JL, Fiere D, Bacigalupo A, Frassoni F, Gorin NC.
    Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S.
    Clin Transpl; 1996 Nov; ():281-90. PubMed ID: 9286578
    [Abstract] [Full Text] [Related]

  • 7. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation.
    Hiraoka A, Ohashi Y, Okamoto S, Moriyama Y, Nagao T, Kodera Y, Kanamaru A, Dohy H, Masaoka T, Japanese FK506 BMT(Bone Marrow Transplantation) Study Group.
    Bone Marrow Transplant; 2001 Jul; 28(2):181-5. PubMed ID: 11509936
    [Abstract] [Full Text] [Related]

  • 8. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
    Lee CK, deMagalhaes-Silverman M, Hohl RJ, Hayashi M, Buatti J, Wen BC, Schlueter A, Strauss RG, Gingrich RD.
    Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
    [Abstract] [Full Text] [Related]

  • 9. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M, Perrin MC, Belhabri A, Molina L, Nicolini F, Tigaud JD, Sotto JJ, Guyotat D, Fière D, Archimbaud E.
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [Abstract] [Full Text] [Related]

  • 10. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
    Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM.
    N Engl J Med; 1993 Oct 21; 329(17):1225-30. PubMed ID: 8413388
    [Abstract] [Full Text] [Related]

  • 11. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL, Bloom EJ.
    Clin Pharm; 1993 Oct 21; 12(10):736-61. PubMed ID: 8258255
    [Abstract] [Full Text] [Related]

  • 12. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants.
    Abdel-Mageed A, Graham-Pole J, Del Rosario ML, Longmate J, Ochoa S, Amylon M, Elfenbein GJ, Janiec J, Jansen J, Lazarus HM.
    Bone Marrow Transplant; 1999 May 21; 23(9):929-32. PubMed ID: 10338049
    [Abstract] [Full Text] [Related]

  • 13. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels.
    Cottler-Fox M, Lynch M, Pickle LW, Cahill R, Spitzer TR, Deeg HJ.
    Bone Marrow Transplant; 1991 Jul 21; 8(1):27-33. PubMed ID: 1655138
    [Abstract] [Full Text] [Related]

  • 14. Acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Perreault C, Gyger M, Boileau J, Bonny Y, Cousineau S, Lacombe M, Lavallee R, Tawil E, D'Angelo G.
    Can Med Assoc J; 1983 Nov 01; 129(9):969-74. PubMed ID: 6367917
    [Abstract] [Full Text] [Related]

  • 15. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
    van Burik JA, Carter SL, Freifeld AG, High KP, Godder KT, Papanicolaou GA, Mendizabal AM, Wagner JE, Yanovich S, Kernan NA.
    Biol Blood Marrow Transplant; 2007 Dec 01; 13(12):1487-98. PubMed ID: 18022579
    [Abstract] [Full Text] [Related]

  • 16. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y, Nagatoshi Y, Kawano Y, Okamura J.
    Bone Marrow Transplant; 2003 Jul 01; 32(2):171-6. PubMed ID: 12838282
    [Abstract] [Full Text] [Related]

  • 17. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis.
    Carlens S, Ringdén O, Remberger M, Lönnqvist B, Hägglund H, Klaesson S, Mattsson J, Svahn BM, Winiarski J, Ljungman P, Aschan J.
    Bone Marrow Transplant; 1998 Oct 01; 22(8):755-61. PubMed ID: 9827972
    [Abstract] [Full Text] [Related]

  • 18. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H, Kitaori K, Kasai M, Shimokawa T, Kato C, Yamanishi H, Ueda R, Morishima Y.
    Int J Hematol; 1999 Jan 01; 69(1):27-35. PubMed ID: 10641440
    [Abstract] [Full Text] [Related]

  • 19. Risk factors for acute graft-versus-host disease in 325 consecutive bone marrow recipients.
    Hägglund H, Boström L, Ringdén O, Nilsson B, Remberger M.
    Transplant Proc; 1994 Jun 01; 26(3):1821-2. PubMed ID: 8030154
    [No Abstract] [Full Text] [Related]

  • 20. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR, German Cooperative Transplant Study Group.
    Ann Hematol; 2003 Jun 01; 82(6):336-42. PubMed ID: 12728337
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.